Esketamine reduces the risk of postpartum depression in women undergoing cesarean section: A systematic review and meta-analysis.
Journal of psychiatric research March 1, 2025 Lőrinc Frivaldszky, Kincső Lőrincz, Jakub Hoferica et al. 4 citations
Perioperative administration of esketamine to women undergoing cesarean section is associated with a lower rate of postpartum depression (PPD) at 3–7 days and 28–42 days after delivery, with odds ratios of 0.43 and 0.59, respectively. Edinburgh Postnatal Depression Scale scores were also significantly lower at 3–7 days postpartum. The analysis, based on 17 eligible trials, suggests that esketamine is safe compared to placebo or standard care. PPD affects 14% of women after childbirth.